CTOs on the Move

Vidara Therapeutics

www.vidararx.com

 
Vidara Therapeutics is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.vidararx.com
  • 2475 Northwinds Pkwy
    Alpharetta, GA USA 30009
  • Phone: 877.305.7704

Executives

Name Title Contact Details

Similar Companies

Professional Imaging Consultants

Professional Imaging Consultants is a Winter Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sojournix

Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women’s health and neuroendocrine disorders.

Nemus Bioscience

Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience Inc. is developing a novel and proprietary class of product candidates that are designed to target the body`s nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics. NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS. To become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.

Alltrna

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna`s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.